



Chers collègues, Chers adhérents,

Le GMP vous invite à un workshop intitulé "**Transporter mediated toxicity prediction with integrated in-vitro/in-silico approach using DILIsym**" co-animé par **Solvo Biotechnology, Cyprotex et Simulations Plus**. Ce workshop se déroulera **le mercredi 6 juillet 2022 de 9H30 à 17h30 (CEST) aux espaces Diderot, Paris (12<sup>ème</sup>)**. Les inscriptions sont ouvertes jusqu'au 30 juin 2022. Le nombre de places est limité à 25 sur la base du premier inscrit, premier servi !

Pour vous enregistrer, merci d'utiliser le lien ci-dessous :

<https://docs.google.com/forms/d/1QEZVLBBXnn-HZb8LWxlRtSLMyrCTFVZWNTeCr9A4--E>

*Ce workshop sera en **anglais**.*

**Frais d'enregistrement (date limite 30 juin 2022):**

- Prix pour académique : 150 € (100 € pour l'enregistrement + 50 € d'adhésion au GMP)
- Prix standard : 300€ (250 € pour l'enregistrement + 50 € d'adhésion au GMP)
- Le paiement pourra se faire par carte bancaire via le site GMP (<http://app.gmp.asso.fr/dons>) en utilisant « Make a donation ». Si vous souhaitez payer par virement bancaire, veuillez contacter [fabrice.hurbin@sanofi.com](mailto:fabrice.hurbin@sanofi.com).

Nous espérons vous voir nombreux à ce workshop.

Bien cordialement,

Le Conseil d'Administration du GMP

\*\*\*\*\*

Dear Colleagues and Members,

The GMP is happy to invite you to a one-day workshop on "**Transporter mediated toxicity prediction with integrated in-vitro/in-silico approach using DILIsym**" jointly presented by **Solvo Biotechnology, Cyprotex and Simulations Plus** on the **6<sup>th</sup> of July 2022 from 9.30h to 17.30h (CEST) at Espaces Diderot, Paris**. Please register for the workshop before the 30th of June 2022. The number of participants is limited to 25 only based on a first-come, first-served.

Please Register by link:

<https://docs.google.com/forms/d/1QEZVLBBXnn-HZb8LWxlRtSLMyrCTFVZWNTeCr9A4--E>

*The instructions for the workshop will be in ENGLISH.*

**Registration fees (Deadline 30<sup>th</sup> June 2022):**

- Academic rate: 150 € (100 € for registration + 50 € for membership)
- Standard rate: 300€ (250 € for registration + 50 € for membership)
- Payment could be done by credit card via the GMP site (<http://app.gmp.asso.fr/dons>) using "Make a donation". If you want to pay by bank transfer, please contact at [fabrice.hurbin@sanofi.com](mailto:fabrice.hurbin@sanofi.com).

We are looking forward to having your participation in the workshop.

GMP, France

**Group of Metabolism and Pharmacokinetics (GMP), France is organizing**  
**Workshop on**  
**Date: 6<sup>th</sup> of July 2022**  
**Venue: Espaces Diderot,**  
**Address: 10 Rue Traversière, 75012, Paris**

**Transporter mediated toxicity prediction with integrated *in-vitro/in-silico* approach using DILIsym**

**Draft Program for the workshop\*:**

<b>Time</b>	<b>Title</b>	<b>Partners</b>
9.30-10h	Introduction of QSP and DILIsym	SIMULATIONS PLUS
10-11h	Introduction to DILI, Pharmaceutical context, importance, types and subcellular mechanisms, transporter involvement	SOLVO BIOTECHNOLOGY
11-11h30	Introduction of Transporter assays for testing BSEP, MRP3-4, NTCP and MDR3, how to obtain <i>in vitro</i> data for <i>in silico</i> modeling – Part 1	SOLVO BIOTECHNOLOGY
11.30h-11.35h	Break	
11h35-12h	Introduction of Transporter assays for testing BSEP, MRP3-4, NTCP and MDR3, how to obtain <i>in vitro</i> data for <i>in silico</i> modeling – Part 2	SOLVO BIOTECHNOLOGY
12-13h	Utilizing <i>in vitro</i> mechanistic assays in DILI risk assessment	CYPROTEX
13h-14h	Lunch	
14h-15.30h	QSP modeling by DILIsym	SIMULATIONS PLUS
15.30h-15.45h	Break	
15.45h-17.30h	Quantitative analysis of mechanisms in DILIsym, Conclusions	SIMULATIONS PLUS

\*The instructions for the workshop will be in ENGLISH.



## Speakers Biography:

### SOLVO BIOTECHNOLOGY



#### **Dr. Zsuzsanna Gáborik**

Associate Director, R&D

Zsuzsanna Gáborik received a master's degree in Bioengineering from the University of Technology and Economics, Budapest. She earned her PhD in Cellular and Molecular Physiology at the Semmelweis University, Budapest, and started her academic carrier at the Department of Physiology at Semmelweis University, focusing on the molecular mechanism of GPCR activation and trafficking. She joined SOLVO in 2011 and took over the operational management of the Research and Development Laboratory in 2016. She is currently the Head of Research and Development, overseeing assay- and cell line developments, research projects and special customer projects. To date, she has contributed to 24 peer reviewed scientific publications.



#### **Dr. Noémi Szili**

Scientific Marketing Manager

Noémi Szili obtained her master's degree in genetics and Cell biology at Université Paris Diderot in 2013. She obtained her PhD in microbiology from Bio Sorbonne Paris Cité specialized in Microbiology in 2017. During her time in Paris, she was involved in multiple research projects at the Pasteur Institute, including the study of bacterial ABC transporters. She started her professional career at SOLVO – a Charles River company in 2018 in a Scientific Business Development role and was promoted to Scientific Marketing Manager in 2021. She is responsible for most scientific marketing collateral in support of SOLVO's portfolio. Serving as scientific liaison, she also works closely with the local commercial team, R&D group and management, and is a member of Charles River's Discovery Advocates scientific advisory group. Noémi has published multiple research articles, is a co-author in the latest SOLVO Transporter book, and regularly hosts webinars and trainings.

## SIMULATIONS PLUS



**Dr. Zackary Kenz**  
Senior Scientist

Zackary Kenz received a PhD in applied mathematics from North Carolina State University in Raleigh, NC. He worked in modeling and simulation at MIT Lincoln Laboratory before joining the DILIsym division of Simulations Plus in 2017. He has explored the role of the immune system in multiple organ systems and disease areas, concentrating on how systems modeling can inform drug development questions. He has contributed to the development of quantitative systems toxicology/pharmacology platforms DILIsym®, RENAsym™, NAFLDsym®, and IPFsym™, and led the development of ILDsym™. He also utilizes these platforms in proprietary projects to help evaluate injury risk or potential efficacy for sponsor compounds in clinical development.



**Dr. Maxime Le Merdy**  
Senior Scientist

Maxime Le Merdy is now a Senior Scientist at Simulations Plus, the world leader company in innovative modeling and simulation software applied to the pharmaceutical research and development. Before joining Simulations Plus, Dr. Le Merdy received a PharmD from University Paris-Descartes in 2015. In 2014, he received his master's degree in Pharmacometrics from the same university. He joined the FDA in 2017 as a post-doctoral fellow in the Division of Quantitative Method and Modeling within the Office of Generic Drugs, where he developed his expertise in PBPK models for locally acting drug products and published multiple paper on ocular delivery models. Prior to this experience, he published on Ethyl-glucuronide, a biomarker of alcohol consumption as well as the physiological modification affecting children's pharmacokinetics.

## CYPROTEX



### **Dr. Paul Walker**

VP Head of Toxicology and Innovation Efficiency

Paul Walker is the VP Head of Toxicology and Innovation Efficiency at Cyprotex where he is responsible for the R&D strategy, operations and study management performed within the Toxicology Group. Paul obtained his PhD from King's College London in Molecular Toxicology and was awarded the Tadion-Rideal prize for molecular sciences (2004). Paul joined Cyprotex in 2010 with his research interests focused on the role of drug metabolism in drug toxicity and *in vitro* assays to predict toxicity in early drug discovery. His team are focused on: 1. Developing and evaluating novel cellular systems to improve the prediction of toxicity. 2. Evaluate current industry utilized mechanistic endpoint assays in predicting toxicity. 3. The importance of drug metabolism and appropriate cellular models in our mechanistic understanding of toxicity. 4. Integrating *in vivo* exposure in interpretation of *in vitro* data, and 5. Modelling approaches combining ADME, PK, Omics technologies and *in vitro* Tox assays to predict toxicity.